168 related articles for article (PubMed ID: 35753673)
1. Factors for recurrence in acute central serous chorioretinopathy patients underwent one-third dose verteporfin photodynamic therapy.
Zhang X; Zhuang X; Dong J; Fu B; Xu L
Photodiagnosis Photodyn Ther; 2022 Sep; 39():102984. PubMed ID: 35753673
[TBL] [Abstract][Full Text] [Related]
2. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
Matušková V; Vysloužilová D; Uher M
Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
[TBL] [Abstract][Full Text] [Related]
3. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.
Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ
Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Noh SR; Kang MS; Kim K; Kim ES; Yu SY
Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247
[TBL] [Abstract][Full Text] [Related]
5. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.
Shinojima A; Kawamura A; Mori R; Fujita K; Yuzawa M
Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105
[TBL] [Abstract][Full Text] [Related]
6. Isolated pigment epithelium detachment: evidence for relation to central serous chorioretinopathy and effect of photodynamic therapy.
Arif F; Pryds A; Larsen M
Acta Ophthalmol; 2018 Dec; 96(8):821-827. PubMed ID: 30246489
[TBL] [Abstract][Full Text] [Related]
7. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
Gulkas S; Sahin O
Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613
[TBL] [Abstract][Full Text] [Related]
8. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy.
Hayashida M; Miki A; Honda S; Nakamura M
Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.
Arf S; Hocaoglu M; Sayman Muslubas I; Karacorlu M
Int Ophthalmol; 2017 Jun; 37(3):483-489. PubMed ID: 27392913
[TBL] [Abstract][Full Text] [Related]
10. PHOTODYNAMIC THERAPY FOR SYMPTOMATIC SUBFOVEAL RETINAL PIGMENT EPITHELIAL DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: Outcomes and Prognostic Factors.
Hwang S; Kang SW; Kim SJ; Jang JW; Kim KT
Retina; 2019 Jun; 39(6):1117-1124. PubMed ID: 29517581
[TBL] [Abstract][Full Text] [Related]
11. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.
Lai TY; Chan WM; Li H; Lai RY; Liu DT; Lam DS
Br J Ophthalmol; 2006 Jul; 90(7):869-74. PubMed ID: 16597666
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Son BK; Kim K; Kim ES; Yu SY
Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
[TBL] [Abstract][Full Text] [Related]
13. Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
Kumashiro S; Takagi S; Itokawa T; Tajima A; Kobayashi T; Hori Y
BMC Ophthalmol; 2021 May; 21(1):241. PubMed ID: 34053440
[TBL] [Abstract][Full Text] [Related]
14. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.
Arevalo JF; Espinoza JV
Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1159-66. PubMed ID: 21448811
[TBL] [Abstract][Full Text] [Related]
15. Reduced-fluence photodynamic therapy for subfoveal serous pigment epithelial detachment with choroidal vascular hyperpermeability.
Goto S; Gomi F; Ueno C; Nishida K
Am J Ophthalmol; 2012 Nov; 154(5):865-871.e1. PubMed ID: 22840480
[TBL] [Abstract][Full Text] [Related]
16. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy.
Pryds A; Larsen M
Acta Ophthalmol; 2012 Dec; 90(8):738-43. PubMed ID: 21586096
[TBL] [Abstract][Full Text] [Related]
17. One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy.
Pichai J; Vanchalerm B; Mansing R
BMC Ophthalmol; 2021 Jan; 21(1):30. PubMed ID: 33430812
[TBL] [Abstract][Full Text] [Related]
18. CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Early and Late Morphological and Functional Changes After Verteporfin Photodynamic Therapy.
Iacono P; Tedeschi M; Boccassini B; Chiaravalloti A; Varano M; Parravano M
Retina; 2019 May; 39(5):980-987. PubMed ID: 29346241
[TBL] [Abstract][Full Text] [Related]
19. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.
Vasconcelos H; Marques I; Santos AR; Melo P; Pires I; Figueira J; de Abreu JF; Cachulo ML; Silva R
Graefes Arch Clin Exp Ophthalmol; 2013 Jul; 251(7):1697-705. PubMed ID: 23389551
[TBL] [Abstract][Full Text] [Related]
20. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
